Rusha Modi MD MPH

On health, AI, power, and the biology of ambition.

[Rusha Modi MD MPH @RushaModi]

Wellness is no longer adjacent to luxury. It is the new luxury vertical.
Hermès is competing with @Function for share of wallet among the same buyer.

[Rusha Modi MD MPH @RushaModi]

Oura may be the first company to monetize biological intent.

Google learned what you wanted from what you searched.

Oura wants to infer what you need from what your body does.

Its IPO filing reports 5 million paid members, 85% twelve-month retention and nearly 42 billion hours of biometric data. It says the hardware sale recovers customer-acquisition cost immediately.

The customer effectively pays Oura to install the sensor that begins modeling their body.

Today’s flywheel is:

More wear → more data → better models → better insights → greater retention.

But that is only an engagement flywheel. The larger business begins when Oura learns what happens after an insight:

Signal → Recommendation → Transaction → Outcome → Better recommendation.

Oura already connects members to glucose data, laboratory testing, LillyDirect, sleep-care pathways, AI navigation and physicians.

Persistent breathing changes could trigger a sleep study. A GLP-1 user showing deteriorating recovery could be routed toward nutritional assessment, strength intervention or DEXA.

Then Oura observes whether the intervention worked.

That outcome-linked dataset would be harder to reproduce than the ring. Apple can build sensors. An EHR can record diagnoses. Oura could connect the person before concern, the action taken and the physiological response afterward.

That makes Oura a demand-and-learning layer for healthcare.

First Oura learns what your body needs. Eventually it may use that continuity to help prove that you are you.

Buried in the filing is a stranger possibility: Oura is exploring payments, identity and access control.

The ring could become a password.

In an internet filling with synthetic faces, voices and text, identity will increasingly require evidence that a persistent human exists behind the account.

A device that has continuously learned your sleep, movement, cardiovascular rhythms, temperature patterns and physical presence holds something harder to fabricate than a password—or perhaps even a face.

Not merely who you claim to be, but the living continuity of being you.

The ten-year Oura could become a portable biological identity layer: authenticating the person and authorizing access to money, records, spaces and care.

The ring may survive because it is discreet, continuously worn and socially acceptable in a way most medical devices are not. But eventually the device is secondary. The product is a persistent biological account that travels across sensors.

When the same company detects the concern, recommends the solution and participates in the transaction, health guidance begins to resemble advertising.

And a system capable of authenticating your identity may also possess an intimate model of your body.

That is the real IPO wager.

Not whether Oura can sell more rings.

Whether the first scaled model of your biological self becomes the gateway to healthcare—and a powerful signal that a persistent human exists behind the account.

[Rusha Modi MD MPH @RushaModi]

@BKRBusinessMin Alpha school but for med school ? @Alphaschool

[Rusha Modi MD MPH @RushaModi]

Luxury is moving beyond selling what you own toward organizing how you live.

Omega can sell you a watch. The promise of more time is a much more powerful sale.

In a High Touch interview, Chris Black describes visiting a beautiful longevity retreat. The facilities were extraordinary. The experience was isolating. He ate soup, stared out the window and felt too weak to use the gym.

The best part, he joked, was the custom Birkenstocks.

That detail captures a problem at the heart of luxury wellness: you can purchase all the surroundings of a better life and still find yourself having a worse afternoon.

Julia Klim recently described the “luxury-ization of fitness”: gyms becoming clubs, recovery becoming hospitality, access becoming part of the product.

I think this helps explain why fitness is converging with aesthetics, longevity and medicine.

The customer wants to look attractive, move comfortably, have energy for work and remain present for the people they love. These industries sell different pieces of a life the customer experiences as one.

Bringing them together makes sense. A physician, trainer and dermatologist who actually coordinate could save someone considerable confusion and wasted effort. A welcoming space can make a difficult routine easier to sustain.

The body is where all four promises meet: fitness offers capability, aesthetics offers appearance, medicine offers protection and repair, and longevity offers more time.

Luxury can organize them into one desirable way of living. Adding medicine gives that promise a different kind of authority.

An expensive purchase can now feel responsible. Appearance, pleasure and fear of aging can share a budget labeled “health.”

None of those motives makes the customer foolish. Wanting more years with your children is deeply human. So is wanting to feel desirable while you live them.

But their combination creates a commercial temptation: almost any upgrade can be presented as something your future self needs.

For a wellness brand, the question is whether people keep buying because the product earns its place in their lives, or because the marketing keeps making them afraid to stop.

For a concierge doctor, the question is whether the fee buys better judgment or a longer list of interventions.

There is a valuable business in coordinating care, removing friction and making useful habits pleasurable. Its premium should survive a physician saying, “You don’t need that test.”

The harder business to defend is one whose renewal depends on finding something new to sell every time the customer starts feeling okay.

That is the boundary I would watch as these industries converge: can the company remain valuable when the customer needs less?

The most credible promise luxury medicine could make is also its hardest commercial test:

We will keep taking care of you, even when there is nothing more to sell you.

[Rusha Modi MD MPH @RushaModi]

The most revealing sentence in a recent longevity interview wasn’t about peptides, sauna or cold plunges.

It was: “I hate all that data shit.”

The speaker doesn’t weigh himself or track his sleep. He wants to know whether he feels good and looks better.

He also gets blood drawn quarterly, takes custom vitamins, thyroid medication, clomiphene, DHEA and sermorelin—all overseen by a concierge physician.

At first, the contradiction seemed almost comic.

Then I realized: he hasn’t rejected optimization. He has outsourced the anxiety of it.

His doctor holds the data. He gets to inhabit the body.

The same logic explains why he will pay for beautiful skincare, weekly massage and wet cupping, but considers bottled water at a restaurant a scam. He isn’t consistently pro-science, anti-science, luxurious or frugal.

He will pay when he can feel the difference: relief, beauty, attention, pleasure, control. He revolts when he suspects someone is selling status at a markup—or asking him to surrender his judgment to a number.

This matters because there is no single “longevity consumer.”

People are not simply trying to live longer. They are trying to answer a more intimate question:

Who gets to interpret my body?

Some give that authority to an Oura score. Others to a concierge physician, ancestral living, lab panels, peptides or intuition. The products differ, but each offers a preferred relationship with uncertainty.

This changes how wellness companies should go to market. Two affluent 44-year-old men may want the same outcome and require opposite products. One wants dashboards, biomarkers and measurable experiments. The other wants a beautiful ritual, a perceptible benefit and an expert quietly handling the complexity.

Demographics will not explain that difference. Worldview will.

The best brands will decide what kind of proof their customer trusts, what improvement should feel like and how much uncertainty the customer wants to carry. They will understand that design can improve adherence, but cannot rescue an ineffective product—and that sometimes the most persuasive luxury signal is telling someone not to buy something.

It changes concierge medicine, too. Some patients want every data point. Others are paying precisely not to think about every data point.

The physician’s job is not to abandon rigor for vibes. It is to place rigor at the right depth: visible when it helps, quiet when it burdens, unavoidable when safety is at stake.

Because “I feel better” is meaningful evidence for pain, sleep and quality of life. It is dangerously incomplete for thyroid excess, arrhythmias, insulin resistance or diseases that remain silent until they are not.

That is the tension modern wellness has not resolved:

The quantified self can become a prison.
The unquantified self can become a mark.

The next great longevity company will not win by producing the largest dashboard or the longest menu of therapies. It will combine three things the market usually separates: an experience people desire, evidence they can trust and governance that protects them when perception is not enough.

The real product is not more data.

It is evidence without epistemic burden.

[Rusha Modi MD MPH @RushaModi]

high-touch longevity is not primarily a testing business. It is a burden-removal business. The client does not actually want more dashboards. She wants someone trustworthy to decide what matters, coordinate the professionals, convert evidence into pleasant rituals, and tell her what she can safely ignore.

[Rusha Modi MD MPH @RushaModi]

The most dangerous use of longevity medicine may not be extending life. It may be extending misalignment.

We now have increasingly powerful ways to keep people functional: better sleep protocols, metabolic drugs, hormone optimization, stimulants, meditation, wearables, supplements, and precision diagnostics.

These tools can change lives.

But they can also help someone tolerate a life that needs to change.

A person becomes metabolically healthier so they can sustain the work that is hollowing them out. They regulate their nervous system so they can remain inside an intolerable relationship. They optimize recovery—not to live more fully, but to return more efficiently to the source of their depletion.

This is not an argument against treatment. Pain is not always a message. Anxiety is not always intuition. Fatigue may be disease, not destiny.

But every intervention should eventually confront a deeper question:

What is this restored capacity for?

If longevity only helps us tolerate the wrong life for longer, it has confused endurance with health.

The highest purpose of consumer biology is not to make dysfunction sustainable. It is to give people enough energy, time, and agency to build lives worthy of being extended.

[Rusha Modi MD MPH @RushaModi]

Intelligence is becoming abundant. Accountable action remains scarce.

The consequential healthcare AI companies won’t merely tell clinicians what they might do. They will earn the right to complete more of the work- and prove that patients are safer because they did.

[Rusha Modi MD MPH @RushaModi]

Healthcare AI companies are obsessed with accumulating proprietary data.

They should be accumulating proprietary permission to act.

I call this care capital, and it may become the real moat in clinical AI. 🧵

[Rusha Modi MD MPH @RushaModi]

The hierarchy is:

Insight → Workflow → Action → Accountability → Care capital.

Institutional permission is not proof of safety. It must be re-earned through outcomes, calibrated deferral, auditability and competent handling of exceptions.

[Rusha Modi MD MPH @RushaModi]

The peptide boom is not merely a longevity story.

It is an early chapter in the labor politics of the programmable body.

[Rusha Modi MD MPH @RushaModi]

The next corporate arms race may not be AI.

It may be physiology.

Peptide companies are moving beyond bodybuilders and biohackers to target founders and executives. One entrepreneur even wants peptides offered as a corporate benefit.

That should get our attention.

[Rusha Modi MD MPH @RushaModi]

Natural humans vs. enhanced humans is the wrong frame.

The real divide is agency vs. capture:

Does technology help your body carry a consequential life—or merely help your body endure one that is consuming it?